Covalent Modification of PML by the Sentrin Family of Ubiquitin-like Proteins*

  1. Tetsu Kamitani,
  2. Hung Phi Nguyen,
  3. Katsumi Kito,
  4. Taeko Fukuda-Kamitani and
  5. Edward T. H. Yeh
  1. From the Division of Molecular Medicine, Department of Internal Medicine, and Research Center for Cardiovascular Diseases, Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas-Houston Health Science Center, Houston, Texas 77030

    Abstract

    PML, a RING finger protein with tumor suppressor activity, has been implicated in the pathogenesis of acute promyelocytic leukemia that arises following a reciprocal chromosomal translocation that fuses the PML gene with the retinoic acid receptor α (RARα) gene. Immunocytochemical analysis has demonstrated that PML is co-localized with a novel ubiquitin-like protein in the nuclear bodies, which could be disrupted by the PML-RARα fusion protein. The physical nature of this co-localization is unknown. Using a COS cell expression system, we show that PML is covalently modified by all three members of the sentrin family of ubiquitin-like proteins. Covalent modification of PML requires the conserved Gly residue near the C termini of sentrin proteins. Sentrinization of PML is highly specific because neither NEDD8 nor ubiquitin could modify PML. Similar specificity is also observed for the covalent modification of RanGAP1 by the sentrin member of ubiquitin-like proteins. These observations highlight the fine substrate specificity of the sentrinization pathway. In acute promyelocytic leukemia, two forms of PML-RARα fusion proteins have been reported. Remarkably, both forms of PML-RARα fusion proteins could not be sentrinized. Thus differential sentrinization of PML and PML-RARα could play an important role in regulating the biological function of PML and in the pathogenesis of acute promyelocytic leukemia.

    Footnotes

    • * This work was supported in part by National Institutes of Health Grant HL-45851 (to E. T. H. Y.), an American Heart Association Established Investigator Award (to E. T. H. Y.), and an Arthritis Foundation Irene Dugan Arthritis Investigator Award (to T. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • To whom correspondence should be addressed: Div. of Molecular Medicine, Dept. of Internal Medicine, University of Texas-Houston Health Science Center, 6431 Fannin, Suite 4.200, Houston, TX 77030. Tel.: 713-500-6660; Fax: 713-500-6647; E-mail: eyeh{at}heart.med.uth.tmc.edu.

    • 1 The abbreviations used are: RARα, retinoic acid receptor α; HA, hemagglutinin; HA-PML, HA epitope-tagged PML; PML-RH, RH-tagged PML.

      • Received October 28, 1997.
    « Previous | Next Article »Table of Contents
    • Advertisement
    • Advertisement
    Advertisement